|

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

RECRUITINGPhase 2Sponsored by Teclison Ltd.
Actively Recruiting
PhasePhase 2
SponsorTeclison Ltd.
Started2021-05-20
Est. completion2025-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04701476

Summary

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
* mCRC progressed on at least two lines of standard chemotherapy; or
* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
* Measurable disease
* ECOG 0-1
* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
* Adequate organ function

Exclusion Criteria:

* Prior organ transplantation
* Liver metastasis more than 50%
* Oxygen saturation less than 92% in room air
* Prior autoimmune disorder
* CNS metastasis
* Major GI bleeding in the last 2 months

Conditions5

CancerColorectal Cancer; Lung CancerLiver CancerLiver DiseaseLung Cancer

Locations1 site

University of California, Irvine Medical Center
Orange, California, 92868
Miranda Duronmnduron@hs.uci.edu

Browse More Trials

Cancer trialsLung Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.